1
|
Cruvinel E, Mussulman L, Scheuermann T, Shergina E, He J, Sherman S, Harrington K, Rigotti NA, Tindle H, Zhu SH, Richter K. Hospital-Initiated Smoking Cessation Among Patients Admitted with Behavioral Health Conditions. J Gen Intern Med 2024; 39:1423-1430. [PMID: 38326585 PMCID: PMC11169289 DOI: 10.1007/s11606-024-08646-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Accepted: 01/22/2024] [Indexed: 02/09/2024]
Abstract
BACKGROUND Smoking rates among people living with behavioral health conditions (BHC) range from 30 to 65% and are 2-4 times higher than rates found in the general population. Starting tobacco treatment during a hospital stay is effective for smoking cessation, but little is known regarding treatment response among inpatients with BHC. OBJECTIVE This study pooled data across multiple clinical trials to determine the relative success in quitting among participants with BHC compared to other study participants. PARTICIPANTS Adults who smoke (≥ 18 years old) from five hospital-based smoking cessation randomized clinical trials. DESIGN A retrospective analysis using data from the electronic health record to identify participants with primary diagnoses related to BHC. Recruitment and data analysis were conducted from 2011 to 2016. We used propensity score matching to pair patients with BHC to those with similar characteristics and logistic regression to determine differences between groups. MEASURES The main outcome was self-reported 30-day abstinence 6 months post-discharge. RESULTS Of 6612 participants, 798 patients had a BHC-related primary diagnosis. The matched sample included 642 pairs. Nearly 1 in 3 reported using tobacco medications after hospitalization, with no significant difference between patients with and without BHC (29.3% vs. 31.5%; OR (95% CI) = 0.90 (0.71, 1.14), p = 0.40). Nearly 1 in 5 patients with BHC reported abstinence at 6 months; however, their odds of abstinence were 30% lower than among people without BHC (OR (95% CI) = 0.70 (0.53,0.92), p = 0.01). CONCLUSION When offered tobacco treatment, hospitalized patients with BHC were as likely as people without BHC to accept and engage in treatment. However, patients with BHC were less likely to report abstinence compared to those without BHC. Hospitals are a feasible and promising venue for tobacco treatment among inpatients with BHC. More studies are needed to identify treatment approaches that help people with BHC achieve long-term abstinence.
Collapse
Affiliation(s)
- Erica Cruvinel
- Department of Population Health, University of Kansas Medical Center, Kansas City, KS, USA.
| | - Laura Mussulman
- Department of Population Health, University of Kansas Medical Center, Kansas City, KS, USA
| | - Taneisha Scheuermann
- Department of Population Health, University of Kansas Medical Center, Kansas City, KS, USA
| | - Elena Shergina
- Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA
| | - Jianghua He
- Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA
| | - Scott Sherman
- Department of Population Health, New York University School of Medicine, New York, NY, USA
| | - Kathleen Harrington
- Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Nancy A Rigotti
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Hilary Tindle
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Shu-Hong Zhu
- Department of Family Medicine and Public Health, University of California, San Diego, CA, USA
| | - Kimber Richter
- Department of Population Health, University of Kansas Medical Center, Kansas City, KS, USA
| |
Collapse
|
2
|
Alshehri AS, Algarni AM, Almahdi HAM, Asiri AHH, Asiri HYM, Alsulami AAH, Alasiri HAA, Hassan NKA. Study to determine the epidemiology of treatment-resistant depression among the Saudi Arabian population: A cross-sectional study. JOURNAL OF EDUCATION AND HEALTH PROMOTION 2024; 12:425. [PMID: 38464636 PMCID: PMC10920685 DOI: 10.4103/jehp.jehp_809_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Accepted: 09/04/2023] [Indexed: 03/12/2024]
Abstract
BACKGROUND Depression is a common mental health disorder that affects millions of people worldwide. Globally, major depressive disorder (MDD) is a public health concern; nearly, it affects more than 300 million people. The coronavirus disease 2019 (COVID-19) pandemic lockdown, travel restrictions, social distancing, and COVID-19 vaccine acceptance have aggravated psychological disorders, such as depression and suicidal tendencies. Treatment-resistant depression (TRD) is typically defined as a lack of response to at least two different antidepressant medications or psychotherapies. TRD is common and has been associated with higher comorbidities and prolonged duration of illness, leading to a substantial medical and economic burden. MATERIALS AND METHODS A cross-sectional study was designed to determine the epidemiology and estimate the prevalence of TRD in Abha City, Assir Region, Kingdom of Saudi Arabia. The study includes adult patients who were attended to the psychiatry department and aged 18-65 years diagnosed with major depressive depression. A total of 651 study participants were recruited. RESULTS Of the total 651 depressive disorder cases, 134 (20.6%) were reported as TRD and the remaining 517 (79.4%) were nontreatment-resistant depressive cases. Of the 651 depression participants, 176 (27%) were males and 475 (73%) were females. More than one-quarter (180 (28%)) had been associated with chronic morbidity. One-tenth of the depressive patients were suffering from thyroid disorders, followed by hypertension (10%), autoimmune diseases (10%), and diabetes mellitus (8%). CONCLUSIONS TRD emerged as a threat to public health and challenging psychiatric care providers, and further innovative techniques and effective newer drugs to treat depression need to be researched. The treatment complaint mechanism is warranted, encouraging people to get treatment from the psychiatrist by removing the stigma of mental illness, which is needed to improve the quality of life of TRD patients.
Collapse
Affiliation(s)
- Abdullah S. Alshehri
- Department of Psychiatry, King Khalid University Medical City, Abha, Saudi Arabia
| | - Abdullah M. Algarni
- Family Medicine Consultant, Aseer Central Hospital, Abha, Aseer Region, Saudi Arabia
| | | | | | | | | | | | | |
Collapse
|
3
|
Shang X, E F, Guo K, Yang C, Zhou L, Wu Y, Yang K, Li X. Effectiveness and Safety of Varenicline for Smoking Cessation: An Overview and Meta-analysis. J Addict Med 2023; 17:536-543. [PMID: 37788606 DOI: 10.1097/adm.0000000000001171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
OBJECTIVE An overview, meta-analysis, and trial sequential analysis were conducted to evaluate the efficacy and safety of varenicline for smoking cessation. METHODS Systematic reviews (SRs) and randomized controlled trials evaluating varenicline versus placebo for smoking cessation were included. A forest plot was used to summarize the effect size of the included SRs. Traditional meta-analysis and trial sequential analysis (TSA) were performed using Stata software and TSA 0.9 software, respectively. Finally, the Grades of Recommendation, Assessment, Development, and Evaluation approach was used to assess the quality of evidence for the abstinence effect. RESULTS A total of 13 SRs and 46 randomized controlled trials were included. Twelve review studies showed that varenicline was superior to placebo for smoking cessation. The meta-analysis results showed that, compared with the placebo, varenicline significantly increased the odds of smoking cessation (odds ratio = 2.54, 95% confidence interval = 2.20-2.94, P < 0.05, moderate quality). Subgroup analysis showed that there were significant differences in smokers with disease and general smokers ( P < 0.05). Differences were also found in the follow-up time at 12, 24, and 52 weeks ( P < 0.05). The common adverse events were nausea, vomit, abnormal dreams, sleep disturbances, headache, depression, irritability, indigestion, and nasopharyngitis ( P < 0.05). The TSA results confirmed the evidence for the effect of varenicline on smoking cessation. CONCLUSIONS Existing evidence supports the superiority of varenicline over a placebo for smoking cessation. Varenicline had mild to moderate adverse events but was well tolerated. Future trials should investigate varenicline in combination with other smoking cessation approaches and compare it with other interventions.
Collapse
Affiliation(s)
- Xue Shang
- From the Health Technology Assessment Center/Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China (XS, FE, KG, CY, LZ, YW, KY, XL); Gansu Provincial Hospital, Lanzhou, China (KG); Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China (XS, FE, KG, CY, LZ, YW, KY, XL); Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China (XS, FE, CY, LZ, YW, KY, XL)
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Prasartpornsirichoke J, Pityaratstian N, Poolvoralaks C, Sirinimnualkul N, Ormtavesub T, Hiranwattana N, Phonsit S, Rungnirundorn T. The prevalence and economic burden of treatment-resistant depression in Thailand. BMC Public Health 2023; 23:1541. [PMID: 37573321 PMCID: PMC10422729 DOI: 10.1186/s12889-023-16477-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Accepted: 08/08/2023] [Indexed: 08/14/2023] Open
Abstract
BACKGROUND The objectives of this study were to investigate the proportion of treatment-resistant depression (TRD) among patients with diagnosed major depressive disorder (MDD) and undergoing antidepressant treatment, to estimate the economic cost of MDD, TRD, and non-treatment-resistant depression (non-TRD), and to examine the differences between TRD and non-TRD MDD in a Thai public tertiary hospital. METHODS This was a combined study between retrospective review of medical records and a cross-sectional survey. The sample size was 500 dyads of antidepressant-treated MDD patients and their unpaid caregivers. MDD patients' medical records, the concept of healthcare resource utilization, the Work Productivity and Activity Impairment Questionnaire: depression and mood & mental state versions (WPAI: D, MM), the Class Impairment Questionnaire (CIQ), and the Family Experiences Interview Schedule (FEIS) were applied as the tools of the study. Pearson Chi's square, Fisher's Exact test, and independent T-test were employed for statistical analysis. RESULTS The proportion of TRD was 19.6% among antidepressant-treated MDD patients in a Thai tertiary public hospital. The results of the study indicated that several factors showed a statistically significant association with TRD criteria. These factors included younger age of MDD patients, a younger age of onset of MDD, lower body mass index (BMI), a history of suicide attempts and self-harm, as well as frequent smoking behavior. The annualized economic cost of TRD was 276,059.97 baht per person ($7,668.33), which was significantly higher than that of cost of non-TRD (173,487.04 baht or $4,819.08). The aggregated economic costs of MDD were 96.8 million baht annually ($2.69 M) if calculated from 500 MDD patients and unpaid caregivers. This contributed to the economic cost of TRD 27.05 million baht (98 respondents) and the economic cost of non-TRD 69.74 million baht (402 respondents). CONCLUSIONS The economic burden associated with TRD was significantly higher compared to non-TRD among antidepressant-treated MDD patients. Specifically, both direct medical costs and indirect costs were notably elevated in the TRD group.
Collapse
Affiliation(s)
- Jirada Prasartpornsirichoke
- Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathumwan, Bangkok, 10330, Thailand.
| | - Nuttorn Pityaratstian
- Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathumwan, Bangkok, 10330, Thailand
- Department of Psychiatry, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
| | | | - Naphat Sirinimnualkul
- Department of Psychiatry, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
- Excellence Center for Sleep Disorders, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
| | | | | | - Sasitorn Phonsit
- Department of Psychology, Faculty of Social Sciences, Kasetsart University, Bangkok, Thailand
| | - Teerayuth Rungnirundorn
- Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathumwan, Bangkok, 10330, Thailand
- Department of Psychiatry, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
| |
Collapse
|
5
|
Carrasco-Garrido P, Fernández-de-Las-Peñas C, Hernández-Barrera V, Palacios-Ceña D, Jiménez-Trujillo I, Gallardo-Pino C. Benzodiazepines and Z-hypnotics consumption in long-COVID-19 patients: Gender differences and associated factors. Front Med (Lausanne) 2022; 9:975930. [PMID: 36160133 PMCID: PMC9493021 DOI: 10.3389/fmed.2022.975930] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Accepted: 08/22/2022] [Indexed: 11/13/2022] Open
Abstract
BackgroundPsychotropic drug consumption has increased during the COVID-19 pandemic. We describe here the prevalence and identifying factors associated with Benzodiazepine (BZD) and Z-hypnotics use among a sample of Spanish adults suffering from long-COVID-19 syndrome, from a gender perspective.Materials and methodsData were anonymously collected between 15th December 2021 and 15th March 2022. The collection form consisted of several questions gathering sociodemographic information, post-COVID symptom, health profile, and pharmacological drug intake. Using logistic multivariate regression models, we estimated the independent effect of each of these variables on self-medicated consumption. Three models were generated (female, male, and both gender).ResultsPrevalence of BZD and Z-hypnotics use was 44.9% (46.5% for women; 37.8% for men). Zolpidem was the most consumed drug among male (20.7%), and lorazepam in female (31.1%). Patterns of drug consumption among female were related with number of post-COVID symptoms and smoking habit (AOR 2.76, 95%CI 1.16–6.52). Males under 40 years of age are more likely to consume BZD and Z-hypnotics (AOR 5.52, 95%CI 1.08–28.27).ConclusionThe prevalence of consumption of BZD and Z-hypnotics in those subjects with long-COVID-19 in our study reaches values of 44.9%. Women with long-COVID-19 declare a higher prevalence of consumption than men. Predictors of BZD and Z-hypnotic in men were, age and number of medication use. Smoking habit and the number of post-COVID symptoms were predictive variables in women.
Collapse
Affiliation(s)
- Pilar Carrasco-Garrido
- Department of Medical Specialties and Public Health, Faculty of Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain
- *Correspondence: Pilar Carrasco-Garrido,
| | - Cesar Fernández-de-Las-Peñas
- Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Faculty of Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain
| | - Valentín Hernández-Barrera
- Department of Medical Specialties and Public Health, Faculty of Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain
| | - Domingo Palacios-Ceña
- Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Faculty of Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain
| | - Isabel Jiménez-Trujillo
- Department of Medical Specialties and Public Health, Faculty of Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain
| | - Carmen Gallardo-Pino
- Department of Medical Specialties and Public Health, Faculty of Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain
| |
Collapse
|
6
|
del Casale A, Paolini M, Gentile G, Borro M, Zocchi C, Fiaschè F, Padovano A, Zoppi T, Modesti MN, De Luca O, Pomes LM, Brugnoli R, Ferracuti S, Girardi P, Pompili M, Simmaco M. Dopamine DRD2 and DRD3 Polymorphisms Involvement in Nicotine Dependence in Patients with Treatment-Resistant Mental Disorders. J Pers Med 2022; 12:jpm12040565. [PMID: 35455685 PMCID: PMC9033085 DOI: 10.3390/jpm12040565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 03/08/2022] [Accepted: 03/28/2022] [Indexed: 12/04/2022] Open
Abstract
Patients affected by mental disorders smoke more than the general population. The reasons behind this habit are genetic, environmental, etc. This study aims to investigate the correlations between some polymorphisms and the smoking habits and nicotine dependence in patients with psychiatric disorders. We recruited 88 patients with treatment-resistant mental disorders, including 35 with major depressive disorder, 43 with bipolar spectrum disorder, and 10 with schizophrenia spectrum disorder. We carried out a clinical and psychometric assessment on current smoking habits, years of smoking, number of daily cigarettes, and level of nicotine addiction. The patients performed a peripheral blood sample for DNA analyses of different polymorphisms. We searched for correlations between the measures of nicotine addiction and analysed genotypes. The expression of the T allele of the DRD2 rs1800497 and DRD3 rs6280 polymorphisms significantly correlated with a lower level of nicotine dependence and lower use of cigarettes. We did not find significant correlations between nicotine dependence and OPRM1 rs1799971, COMT rs4680 and rs4633 polymorphisms, CYP2A6 rs1801272 and rs28399433, or 5-HTTLPR genotype. Concluding, DRD2 rs1800497 and DRD3 rs6280 polymorphisms are involved in nicotine dependence and cigarette smoking habits in patients with treatment-resistant mental disorders
Collapse
Affiliation(s)
- Antonio del Casale
- Department of Dynamic and Clinical Psychology, and Health Studies, Faculty of Medicine and Psychology, Sapienza University, Via degli Apuli 2, 00185 Rome, Italy;
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Correspondence: ; Tel.: +39-0633777774
| | - Marco Paolini
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Giovanna Gentile
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
- Unit of Laboratory and Advanced Molecular Diagnostics, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy
| | - Marina Borro
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
- Unit of Laboratory and Advanced Molecular Diagnostics, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy
| | - Clarissa Zocchi
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Federica Fiaschè
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Alessio Padovano
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Teodolinda Zoppi
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Martina Nicole Modesti
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Ottavia De Luca
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
- Unit of Laboratory and Advanced Molecular Diagnostics, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy
| | - Leda Marina Pomes
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
- Unit of Laboratory and Advanced Molecular Diagnostics, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy
| | - Roberto Brugnoli
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Stefano Ferracuti
- Department of Human Neuroscience, Sapienza University, Viale dell’Università 30, 00185, Rome, Italy;
- Unit of Risk Management, ‘Sant’Andrea’University Hospital, Via di Grottarossa, 00189 Rome, Italy
| | - Paolo Girardi
- Department of Dynamic and Clinical Psychology, and Health Studies, Faculty of Medicine and Psychology, Sapienza University, Via degli Apuli 2, 00185 Rome, Italy;
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
| | - Maurizio Pompili
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Maurizio Simmaco
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
- Unit of Laboratory and Advanced Molecular Diagnostics, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy
| |
Collapse
|